December, 08th | 10:39 - 10:42
56-week results from the talon open-label extension, a phase iiib/iv study of brolucizumab in a treat-and-extend regimen with maximum treatment intervals up to 20 weeks in patients with neovascular age-related macular degeneration
DE SANTI NICOLA
Add to calendar
0